Bionano Genomics yesterday morning lowered its 2024 annual revenue guidance to between $32M and $36M, primarily reflecting an expected decrease in OGM instrument placements, down from the previous range provided in August of $36M to $40M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNGO:
- Bionano Genomics lays off 45% of staff, or 84 employees
- Bionano Genomics announces departure of CFO Gulsen Kama
- Bionano Genomics downgraded to Neutral from Buy at BTIG
- BioNano Genomics Restructures for Cost Efficiency and Cash Flow Optimization
- Bionano Genomics downgraded at Scotiabank on limited capital market visibility